Compare ICCM & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICCM | CTSO |
|---|---|---|
| Founded | 2006 | 1997 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 45.7M |
| IPO Year | 2013 | 2008 |
| Metric | ICCM | CTSO |
|---|---|---|
| Price | $0.64 | $0.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.50 | ★ $5.38 |
| AVG Volume (30 Days) | ★ 169.8K | 62.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,503,908.00 |
| Revenue This Year | $19.87 | $7.29 |
| Revenue Next Year | $31.38 | $8.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 48.53 |
| 52 Week Low | $0.54 | $0.60 |
| 52 Week High | $1.53 | $1.39 |
| Indicator | ICCM | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 54.12 | 60.02 |
| Support Level | $0.59 | $0.61 |
| Resistance Level | $0.62 | $0.74 |
| Average True Range (ATR) | 0.03 | 0.03 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 69.32 | 78.52 |
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.